SCHEMBL5862774

SCHEMBL5862774

NC(=O)C1(c2ccc(Cl)cc2)CCCC1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.64
HSD11B1 P28845 8/20 0.58
ALDH1A1 P00352 3/20 0.54
LMNA P02545 2/20 0.53
HDAC1 Q13547 1/20 0.49
MAP4K4 O95819 1/20 0.47
FFAR2 O15552 2/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
AKR1C1 Q04828 1/20 0.46
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CHRM2 P08172 1/20 0.44
CHRM1 P11229 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11029291 0.98 HDAC4 (0.62) HDAC4HSD11B1ALDH1A1LMNAHDAC1
SCHEMBL10002416 0.96 HDAC4 (0.59) HDAC4HSD11B1ALDH1A1LMNAHDAC1
SCHEMBL1975025 0.92 HSD11B1 (0.56) HDAC4HSD11B1ALDH1A1LMNASMN1; SMN2
SCHEMBL651440 0.84 DRD2 (0.56) HDAC4HSD11B1ALDH1A1SLC6A4SLC6A3
SCHEMBL2701341 0.84 ALDH1A1 (0.54) HDAC4HSD11B1ALDH1A1LMNAMAP4K4
SCHEMBL503762 0.82 AKR1C1 (0.68) HDAC4HSD11B1ALDH1A1HDAC1MAP4K4
SCHEMBL1627734 0.82 HDAC4 (0.66) HDAC4HSD11B1ALDH1A1LMNAHDAC1
SCHEMBL8184245 0.82 LMNA (0.54) HDAC4HSD11B1ALDH1A1LMNAAKR1C1
SCHEMBL2817645 0.82 LMNA (0.54) HDAC4HSD11B1ALDH1A1LMNAHDAC1
Hydrochloric Acid SCHEMBL8353081 0.82 DRD2 (0.54) HDAC4HSD11B1SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020169203-A1 Ion channel modulating agents NEUROSEARCH A/S (DK) 2002-11-14 US claimed
EP-1140784-A2 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2001-10-10 EP claimed
WO-2000037422-A2 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2000-06-29 WO claimed
US-7012146-B2 Ion channel modulating agents POSEIDON PHARMACEUTICALS A/S (DK) 2006-03-14 US disclosed
US-20020169203-A1 Ion channel modulating agents NEUROSEARCH A/S (DK) 2002-11-14 US disclosed
EP-1140784-A2 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2001-10-10 EP disclosed
WO-2000037422-A2 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2000-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169203-A1 Ion channel modulating agents KCNN3, KCNN1, KCNN2 HDAC4 1092/4885HSD11B1 4518/4885ALDH1A1 4482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.